CLEVELAND, Nov. 3, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac
MRIdian enables a fundamental change from conventional radiotherapy by using diagnostic-quality MR imaging and enabling daily on-table treatment plan adaptation. MRIdian also uniquely allows for continuous MR imaging to automatically control beam delivery to account for subtle anatomical changes that may occur during treatment. Combined, these advancements allow clinicians to tailor the dose more closely to the targeted tumor, potentially mitigating incidental radiation exposure to surrounding healthy tissue and organs.
"Radiation oncology departments are recognizing the value of MR-guidance and its ability to improve the way treatment is visualized, planned and delivered," said Chris Raanes, president and CEO of ViewRay. "This purchase illustrates the shift that's taking place in image-guided radiation therapy and its impact on clinical practice."
The purchase of two MRIdian Linac systems for Rigshospitalet and Herlev Hospitals was part of a collaborative bid with Varian Medical Systems, under which additional Varian treatment machines were also purchased.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements, include those with respect to the mitigation of radiation exposure to healthy tissue and organs, improvements to treatments, and shifts in image guided radiation therapy. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
View original content:http://www.prnewswire.com/news-releases/viewrays-mridian-linac-selected-as-mr-guided-radiotherapy-system-in-danish-tender-300549192.html
SOURCE ViewRay, Inc.
Subscribe to our Free Newsletters!
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...
Strabismus or squint is a failure of the two eyes to maintain proper alignment when looking at an ...View All